Happify Health has launched a digital therapeutic designed to help diagnose and manage major depressive disorder as well as generalized anxiety disorder, as the two conditions often go hand-in-hand.

Leveraging Food and Drug Administration regulations loosened during the pandemic, Happify Health, which is best known for its consumer wellness app, will launch new prescription-only software to treat ...

Happify is taking advantage of relaxed FDA rules to release a prescription-only app for treating people with both major depressive disorder and generalized anxiety disorder. The app, called Ensemble, ...

Digital therapeutics are on the rise and here to stay. Many digital therapeutics are designed for the treatment of mental health conditions, primarily anxiety and depression disorders, and incorporate ...

Happify Inc. launched Ensemble, a prescription digital therapy designed to treat patients with major depressive disorder (MDD) or generalized anxiety disorder (GAD). The app joins several others that ...

Sanofi joins the digital therapeutics market Tuesday with a proposed app to improve mental health in patients with multiple sclerosis. Created in partnership with established mental health digital ...

It should come as no surprise that meditation and mindfulness apps were downloaded more than any category in 2020. People looking to cope with the pandemic, protests, and presidential election ...

IRVINE, Calif.--(BUSINESS WIRE)--University of California, Irvine has published the results of a randomized study in JMIR Serious Games, "Biofeedback via a Smartphone App on Stress Recovery," which ...

New York-based Happify, which makes a mental health assessment platform available via an app or website, has raised $5 million in a new round of funding that will allow the startup to expand its staff ...

Digital therapeutics startup Happify Health raised $73 million in funding. The New York-based company builds app-based tools based on cognitive behavioral therapy and mindfulness. Deerfield Management ...